{
  "pmcid": "10263203",
  "sha256": "74498bb02c7686a0a297f5b8afa690ddd361e1dc87f7466887a3112addf06df4",
  "timestamp_utc": "2025-11-09T15:06:00.225540+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.372616041791371,
    "reading_ease": 44.46371483375961,
    "word_count": 799
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This was a secondary analysis of data from an earlier cluster-randomized trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Between April 2019 and December 2020, 1339 of 1679 eligible patients were included in this study"
      },
      "Intervention": {
        "score": 2,
        "evidence": "the two participating hospitals were randomized to administer aspirin (100 mg daily) or enoxaparin (40 mg daily)"
      },
      "Objective": {
        "score": 1,
        "evidence": "Questions/purposes: (1) Is the type of VTE prophylaxis (enoxaparin or aspirin) used after hip arthroplasty or knee arthroplasty associated with a higher risk of persistent wound drainage?"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Persistent wound drainage was defined as any wound drainage beyond Postoperative Day 3"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "the two participating hospitals were randomized"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Assessors were not blinded to the type of prophylaxis each patient received"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between April 2019 and December 2020, 1339 of 1679 eligible patients were included in this study"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "65 in the enoxaparin group and 49 in the aspirin group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "odds ratio 1.2 [95% confidence interval 0.8 to 1.8]; p = 0.40"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}